# Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

> **NCT00147121** · PHASE2,PHASE3 · COMPLETED · sponsor: **Haruhiko Fukuda** · enrollment: 300 (actual)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** Rituximab + Standard CHOP
- **DRUG:** Rituximab + Bi-weekly CHOP

## Key facts

- **NCT ID:** NCT00147121
- **Lead sponsor:** Haruhiko Fukuda
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2016-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00147121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00147121, "Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00147121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*